|
 |
DelatestrylThis page contains recent news articles, when available, and an overview of Delatestryl but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; MarketWatch Indevus Pharmaceuticals Announces Completion Of Enrollment In ... - Aug 23, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; Medical News Today (press release), Indevus Pharmaceuticals Announces Completion of Enrollment in ... - Aug 22, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; Earthtimes (press release), Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 ... - Aug 5, 2008 Cost of product revenue in the current quarter relate primarily to costs associated with the SANCTURA franchise, VANTAS and DELATESTRYL. MarketWatch Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 ... - Jul 29, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; CNNMoney.com (press release) 2008-07-02 20:27:17 - www.companiesandmarkets.com adds new report ... - 03 Jul 2008 The company´s marketed products are: Sanctura for the treatment of overactive bladder; Delatestryl for treating hypogonadism in men; Supprelin-LA for the PR-Inside.com (Pressemitteilung), Indevus Plunges as US Request Delays Nebido for Two Years - Jun 4, 2008 Indevus, which sells Sanctura for overactive bladders and Delatestryl for low testosterone, needs to expand sales to end five years of losses. Bloomberg Indevus Receives Approvable Letter from FDA for NEBIDO(R) - Jun 30, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; Stockhouse, Indevus Announces Management Changes - Jun 12, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; PR Newswire (press release), BUYINS.NET: MNI, AKNS, IDEV, RBPAA, TSFG, IFLI Have Been Added To ... - Jun 23, 2008 Inc.; VANTAS for treating advanced prostate cancer, SUPPRELIN LA for central precocious puberty, and DELATESTRYL for the treatment of hypogonadism. Trading Markets (press release), Emerging Markets Consulting, LLC.: Emerging Markets Consulting ... - Jun 17, 2008 Inc.; VANTAS for treating advanced prostate cancer, SUPPRELIN LA for central precocious puberty, and DELATESTRYL for the treatment of hypogonadism. Trading Markets (press release), Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor ... - May 16, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; PharmaLive.com (press release), Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR ... - May 22, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; Lifescience-online, Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to ... - Apr 3, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; PR Newswire (press release), Indevus CEO to retire by Sept. 1 - Mar 3, 2008 Indevus makes such drugs as Sanctura, for overactive bladder, Vantas, for advanced prostate cancer, and Delatestryl, for male hypogonadism. Boston Globe, Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and ... - Mar 3, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; Earthtimes, Indevus To Announce First Quarter Fiscal 2008 Financial Results On ... - Jan 31, 2008 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; FOXBusiness Market Review: Indevus Pharmaceuticals, Inc. Under Current ... - Feb 1, 2008 ...for overactive bladder, VANTAS for advanced prostate cancer, SUPPRELIN LA for central precocious puberty, and DELATESTRYL to treat male hypogonadism. Trading Markets (press release), Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) - 20 Dec 2007 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; CNNMoney.com Indevus Pharmaceuticals Announces Fiscal 2007 - Nov 29, 2007 Cost of product revenue in the current quarter relates primarily to sales of SANCTURA to Esprit at cost, costs associated with VANTAS, DELATESTRYL and CNNMoney.com Indevus Pharmaceuticals To Present at RBC Capital Markets Conference - Dec 5, 2007 DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; CNNMoney.com FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus - Nov 1, 2007 DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; CNNMoney.com Sharrock Retires From Indevus Pharmaceuticals Board - Oct 22, 2007 ...for overactive bladder, Vantasfor advanced prostate cancer, Supprelin LA, for central precocious puberty, and Delatestryl to treat male hypogonadism. Trading Markets (press release), Indevus Pharmaceuticals to Present at Think Equity Partners ... - Sep 27, 2007 DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; CNNMoney.com Alkermes and Indevus Announce Positive Results from Phase 2a ... - Sep 26, 2007 DELATESTRYL(R) is Indevus' registered trademark for its DELATESTRYL product. VANTAS(R) is Indevus' registered trademark for its VANTAS product. Genetic Engineering News (press release), Indevus Announces Submission of New Drug Application - Aug 28, 2007 DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; CNNMoney.com Indevus Receives Approvable Letter From FDA for VALSTAR(R) for ... - Aug 17, 2007 VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance CNNMoney.com Indevus Announces Receipt of $49.9 Million Milestone Payment from ... - Aug 13, 2007 The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, DELATESTRYL(R) to treat male CNNMoney.com Indevus Announces FDA Approval of SANCTURA(R) XR - 07 Aug 2007 PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, DELATESTRYL(R) to treat male Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice ... - Jun 29, 2007 CNNMoney.comThe Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, DELATESTRYL(R) to treat male Indevus to Present at the 2007 FBR Growth Conference - May 23, 2007 Earthtimes.orgThe Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male Alkermes and Indevus Announce Initiation of Phase 2a Clinical ... - 26 Apr 2007 PipelineReview.com (press release),DELATESTRYL(R) is Indevus' registered trademark for its DELATESTRYL product. Indevus has pending trademark applications for SANCTURA XR. Indevus Announces Submission of Supplemental NDA to Reintroduce ... - Apr 19, 2007 PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male Valera Pharmaceuticals, Inc. Announces Intention to Delist From ... - Apr 6, 2007 Web Services Journal,The Company's marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. The compounds in development include Valera Pharmaceuticals, Inc. Announces Intention to Delist From ... - Apr 6, 2007 Genetic Engineering News (press release),The Company's marketed products include SANCTURA(R) for overactive bladder and DELATESTRYL(R) to treat male hypogonadism. The compounds in development Biotech Day In Review: MedImmune Puts Itself Up For Sale - Apr 12, 2007 Seeking Alpha,Indevus markets Sanctura for overactive bladder, Delatestryl for male hypgogonadism and other drugs. Valera is developing hydrogel-based implants for Indevus to Present at CIBC Annual Biotechnology & Specialty ... - Apr 5, 2007 PR-Inside.com (Pressemitteilung),...bladder, which it co-promotes with its partner Esprit Pharma, Inc. and DELATESTRYL(R) to treat male hypogonadism. The compounds in development include Alkermes and Indevus Announce Joint Collaboration to Develop ... - Jan 5, 2007 PipelineReview.com (press release),The Company’s marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. The compounds in development include Alkermes and Indevus Announce Joint Collaboration to Develop ... - Jan 4, 2007 PharmaLive.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder and DELATESTRYL(R) to treat male hypogonadism. The compounds in development FDA Accepts New Drug Application For SANCTURA XR(TM) Submitted By ... - Dec 25, 2006 Medical News Today (press release),...conditions. The Company's marketed products include SANCTURA(R) for overactive bladder and DELATESTRYL(R) to treat male hypogonadism. ... Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ... - Dec 7, 2006 Yahoo! News (press release)2006 Highlights -- In January, the Company completed its acquisition of the US rights to DELATESTRYL from Savient Pharmaceuticals. ... Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ... - Dec 7, 2006 PR Newswire (press release),...economic interest in aminocandin's success." 2006 Highlights -- In January, the Company completed its acquisition of the US rights to DELATESTRYL from Savient ... Indevus Pharmaceuticals Announces Fiscal 2006 Year End and Fourth ... - Dec 7, 2006 Drug Newswire (press release),...received from the Company's partner, $7.7 million of SANCTURA royalties, $8.8 million in sales force subsidy and $2.7 million from net sales of DELATESTRYL. ... Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals - Dec 12, 2006 Yahoo! News (press release)...focused portfolio of marketed and late stage products, including SANCTURA® and SANCTURA XR(TM) for overactive bladder, NEBIDO® and DELATESTRYL® for male ... Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals - Dec 12, 2006 Genetic Engineering News (press release),...focused portfolio of marketed and late stage products, including SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, NEBIDO(R) and DELATESTRYL(R) for male ... Indevus Pharmaceuticals to Announce Fiscal 2006 Financial Results ... - Dec 5, 2006 Earthtimes.orgThe Company currently co-promotes SANCTURA(R) for overactive bladder and markets DELATESTRYL(R) to treat male hypogonadism and currently has six compounds in ... Indevus ends fiscal year with 50 percent revenue boost - Dec 7, 2006 Boston Business Journal,Among Indevus' 2006 highlights: The company acquired the US marketing rights to Delatestryl, a drug produced by Savient Pharmaceuticals to treat male ... Indevus Pharmaceuticals (IDEV) Misses Q4 EPS by 2c - Dec 7, 2006 StreetInsider.com (subscription),...received from the Company's partner, $7.7 million of SANCTURA royalties, $8.8 million in sales force subsidy and $2.7 million from net sales of DELATESTRYL. Valera Jumps on Buyout Deal - Dec 12, 2006 BusinessWeekThe Lexington (Mass.) outfit already markets Delatestryl, another therapy for male hypogonadism which requires more frequent injections than Nebido. ... Indevus To Acquire Valera For $120 Mln In Stock Transaction Plus ... - Dec 12, 2006 Trading Markets,...our current focused portfolio of marketed and late stage products, including Sanctura and Sanctura XR for overactive bladder, Nebido and Delatestryl for male ... FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by ... - Dec 13, 2006 Yahoo! News (press release)...conditions. The Company's marketed products include SANCTURA® for overactive bladder and DELATESTRYL® to treat male hypogonadism. ... Indevus sees net loss remaining in mid-teens for next few qrtrs - Dec 7, 2006 ReutersSales of Delatestryl, a marketed injectable testosterone preparation for the treatment of male hypogonadism, are expected to come down in 2007 due to generic ... Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce ... - Dec 5, 2006 Yahoo! News (press release)The Company currently co-promotes SANCTURA® for overactive bladder and markets DELATESTRYL® to treat male hypogonadism and currently has six compounds in ... : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |